Table 2. MEDI4212 Inhibits IgE-mediated functional responses.
| Assay | IgE concentration (MW = 180kDa) | IC50 (95% CI)1 | |
|---|---|---|---|
| MEDI4212 (pM) | Omalizumab (pM) | ||
| FcϵRI-mediated calcium signaling in RBL-ER51 cells | 139 pM (10 IU/mL) | 84 (73–96) (n = 11) |
3254 (2764–3830) (n = 11) |
| Beta-hexosaminidase release from LAD2 mast cell line | 150 pM (11 IU/mL) | 20 (12–35) (n = 4) |
2116 (981–4564) (n = 4) |
| IM9 (CD23) cell binding assay | 56 nM (4167 IU/mL) | 7893 (6075–10260) (n = 3) |
7814 (5206–11730) (n = 5) |
| CD23-mediated phagocytosis assay | 28 nM (2083 IU/mL) | 1337 (192–9316) (n = 3) |
1044 (300–3627) (n = 3) |
CI, confidence interval; FcϵRI, high affinity receptor for IgE; IC50, half maximal inhibitory concentration; IgE, immunoglobulin E; MW, molecular weight; 1IC50 fit of combined data from separate experiments